NeoGenomics (NEO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on NeoGenomics (NEO) is Neutral.

The composite score behind that read is -0.03, weighing +0.06 of bullish evidence against -0.33 bearish.

NeoGenomics last closed at $16.35, +2.06% on the session.

Against the IVW growth benchmark the position is +1.26% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

15 graded predictions for NEO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks NeoGenomics in the 34th percentile on return on equity, where 100 is best.

NeoGenomics is classified under Health Care / Health Care Providers & Services, with a market capitalisation of $2.06B.

StockMap tracks NeoGenomics as the 43rd largest of the 85 companies it covers in the Health Care Providers & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 81 Neutral and 4 Moderate Underperform.

On that composite NeoGenomics ranks 53rd of 85 in the group, against a group median of +0.00.